I wanted to learn more about the company, which is one of the only examples in the World using Gene therapy to treat specific and rare types of blindness.
GenSight is interesting in many ways. It was founded very recently (2012) and has since raised a total of €52M in series A & B rounds from some really top-notch VCs: Versant Ventures, Abingworth & Index Ventures (now Medixci).
Bernard Gilly is a veteran of the Biotech space, and even more so in the ophthalmology field. He founded Fovea Pharmaceuticals in 2009, which he sold to Sanofi’s Vision Institute.
He also co-founded the French Pixium Vision (read our take on it here). He has a deep understanding of the field and a extensive experience in entrepreneurship and financing.